Hikma upgrades FY guidance, cautious on Sudan impact

Hikma Pharmaceuticals upgraded full-year guidance after a stronger-than-expected start to the year for its generics business but expressed concern about the impact of the current conflict in Sudan on operations.

"The safety and wellbeing of our colleagues in Sudan is a top priority and we are doing what we can to support them. Our current guidance does not take into account any potential impact this evolving situation could have on our business. In 2022 sales from Sudan in our branded and injectables businesses represented 2.5% of group revenue," the company said on Friday.

"We have also had a stronger than expected start in our generics business, leading us to upgrade our guidance for the full year."

Reporting by Frank Prenesti for Sharecast.com